Initiatives / VITAL / RSV Baseline
RSV Baseline · ISP 2026001
RSV Baseline: from eligible to vaccinated.
Within 8 weeks, help at least 50 eligible adults self-report receiving an RSV vaccination, while identifying the implementation strategies that most effectively increase evidence-based vaccination.
Why this program
The case for acting now.
Eligible adults remain unvaccinated because of awareness, confidence and access barriers.
A focused RSV program can close this gap while generating real-world implementation insights.
More adults are now eligible for RSV vaccination, creating an opportunity to improve implementation.
Who it's for
The people this program serves.
Adults 50 and older who are eligible for RSV vaccination but remain unvaccinated because of barriers that can be addressed.
Priority indicators
In their words
- “As an adult with COPD, I want to know if I qualify so I can discuss vaccination with my physician.
- “As a caregiver, I want to help my parents find out if they qualify, so they can avoid an RSV hospitalization.
- “As someone who is unsure, I want answers to common questions so I feel confident.
The journey
Every step, from start to finish.
Each Implementation Support Program finds what works and scales it rapidly. Here is the path this one follows.
What it involves
Barriers in, support out.
- Low awareness of eligibility
- No provider recommendation
- Safety and effectiveness concerns
- Scheduling challenges
- Cost and insurance uncertainty
- Competing priorities
- Trusted education
- Reminder journey
- Navigation support
- Discussion aids for clinician visits
- Appointment help
What we measure
Every step, measured.
Also measured
- Vaccination uptake
- Time to vaccination
- Barriers resolved
- Vaccination confidence
- Implementation insights for future vaccine programs
Timeline
8 weeks, from activation to impact report.
Timing depends on partner alignment and on governance, protocol and IRB requirements.
Our commitments
Independent and non-promotional.
All FDA-approved RSV vaccines are presented equally, and no vaccine is endorsed. RSV vaccination is presented as an individual healthcare decision, made by patients with their clinicians.
This program has no sponsor. If a sponsor joins, it will be named here. The program follows a defined protocol, run under AHIS governance and the MONARCH operating standard for implementation measurement. Sponsors may help identify implementation challenges, populations or outcomes of interest. Design, governance and evaluation stay independent. Sponsors receive aggregate, de-identified results only.
Overseen by the AHIS Board in Phase 1 of AHIS governance, and by the Implementation Advisory Committee from Phase 2. Impact reports are shared publicly, including what didn't work.
Get involved.
Share the program with eligible adults, or join as an advocacy or community partner.
